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Background: Screening with ankle-brachial index (ABI) measurement could be clinically relevant to avoid
cardiovascular events in subjects with asymptomatic atherosclerosis. To assess the practical impact of guidelines
regarding the use of ABI as a screening tool in general practice, the corresponding number needed to screen,
including the required time investment, and the feasibility of ABI performance, was assessed.
Methods: An observational study was performed in the setting of 955 general practices in the Netherlands. Overall,
13,038 subjects of ≥55 years presenting with symptoms of intermittent claudication and/or presenting with≥ one
vascular risk factor were included. Several guidelines recommend the ABI as an additional measurement in selected
populations for risk assessment for cardiovascular morbidity.
Results: Screening of the overall population of ≥50 years results in862 subjects per general practice who should
be screened, resulting in a time-requirement of approximately 6 weeks of full time work. Using an existing clinical
prediction model, 247 patients per general practice should be screened for PAD by ABI measurement.
Conclusion: Screening the entire population of ≥50 years will in our opinion not be feasible in general practice. A
more rationale and efficient approach might be screening of subsets of the population of ≥55 years based on a
clinical prediction model.Background
Peripheral arterial disease (PAD) is a common disease,
with a prevalence that increases with age and with the
presence of vascular risk factors. The ankle-brachial-index
(ABI) is a simple, inexpensive diagnostic test for PAD.
Among well-trained operators, reproducibility is excel-
lent, and the validity of the test for a stenosis above 50%
in the arteries of the leg is high, with a sensitivity and
specificity of approximately 80% and 96% respectively
[1]. The ABI measurement as a diagnostic tool is there-
fore a very useful non-invasive tool for identifying symp-
tomatic patients with atherosclerosis in primary care. An
ABI below 0.9 is associated with an important increased* Correspondence: b.bendermacher@live.nl
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distribution, and reproduction in any mediumrisk of cardiovascular morbidity and mortality with a
positive predictive value of 17.6% for a future cardiovas-
cular event [2], and a relative risk of 3.34 for cardiovascu-
lar and cerebrovascular mortality [3]. It is well known
that in symptomatic patients with PAD secondary pre-
vention of a cardiovascular event by risk factor manage-
ment and antiplatelet therapy is effective. However,
subjects with asymptomatic atherosclerosis may well
benefit from the same preventive measures, since the
cardiovascular morbidity rate for asymptomatic PAD
subjects was estimated at 76.8 per 1000 person-years at
risk, compared with 13.6 for the non-PAD population
[4]. Furthermore, much higher all-cause and cardiovas-
cular mortality rates were observed in asymptomatic
PAD subjects (42.8 and 35.8 per 1000 person-years, res-
pectively) compared with non-PAD subjects (10.9 and
2.4 per 1000 person-years, respectively) [4]. Therefore,
screening of asymptomatic subjects at risk is likely to be
clinically useful.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.






0 55 – 59 years Never smoked No hypertension
+ 1 60 – 64 years Hypertension,
adequately treated
+ 2 65 – 69 years Ever smoked
+ 3 70 – 74 years Hypertension,
not adequately
treated
+ 4 75 – 79 years
+ 5 80 – 84 years
+ 6 ≥ 85 years
+ 7 Current smokers
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initiate a primary prevention strategy in all asymptom-
atic subjects is consistent with current international clin-
ical practice guidelines, including the TASC II guideline
[5] and the European Guideline [6]. In earlier guidelines
the initial risk assessment was recommended to be per-
formed using a multifactorial statistical model, such as
the Framingham Risk Score [7,8], to maximize the
benefit-cost ratio of primary prevention treatment [9].
However, it is shown that a low ABI doubled the 10-year
risk of total mortality, cardiovascular mortality, and
major coronary event rate compared with the overall
rate across all Framingham risk categories [10]. The ABI
is recommended as additional measurement in selected
populations, especially in people aged 50 years and older
or those who appear to be at risk and therefore refining
the risk prediction with improvement of the benefit-cost
ratio. Besides, it is shown that the ABI provided inde-
pendent risk information compared with the Framing-
ham Risk Score [10].
Primary care providers are best positioned to deter-
mine the at-risk population in the general population
and to initiate educational, lifestyle, and cardiovascular
risk reduction therapies [11]. However, physicians have
not readily adopted the screening of asymptomatic PAD
in their general practice [12], and studies on the feasibil-
ity of ABI testing for the assessment of overall cardiovas-
cular risk are lacking. Furthermore, to our knowledge, no
guideline provides information on the necessity of
repeating the ABI measurement, let alone its timing in
subjects with a normal ABI (≥0.9) at first screening. Only
for patients with diabetes a recommendation is given to
repeat the ABI measurement every 5 years if the initial
test is normal [13]. One could imagine that in subjects
between 50 and 60 years of age with a normal initial ABI,
the ABI can decrease over time due to the relatively slow
progression of the atherosclerotic process without caus-
ing complaints. It is a possibility that subjects with this
decrease in ABI should be a prime target for aggressive
risk factor management. Hence, it might be preferable to
repeat the ABI measurement for screening of the pres-
ence of PAD, and consequently generalized atheroscler-
osis, in subjects with a normal initial ABI.
To assess the practical impact of the guidelines regard-
ing the use of the ABI as a screening tool for diagnosing
PAD in asymptomatic subjects, the number needed to
screen was explored. The impact of this number needed
to screen on the required time investment by general
practitioners in the Netherlands was studied to be able
to explore the feasibility of the ABI in general practice.
Methods
Contemporary guidelines regarding the advice to per-
form an initial risk assessment for cardiovascularmorbidity in clinical practice, were systematically
searched for indications that an ABI measurement
should be performed. For the guideline search MED-
LINE and websites of guideline development organiza-
tions were used.
To assess the number needed to screen, a composition
of the general population was made using the census of
the Dutch population, provided by the Central Office of
Statistics of the Netherlands, and studies reporting the
prevalence of vascular risk factors in open study popula-
tions, taking into account the age band distribution.
There were 6,087,661 people of 50 years and older with
an overall population size of 16,754,989, corresponding
with a population of 36.7% of 50 years and older.
To investigate an alternative strategy to restrict the
ABI measurement to patients who are at a high risk, the
PREVALENT clinical prediction model was used
(Tables 1 and 2) [14]. This model has been developed by
performing an ABI in 7.454 consecutive patients of
55 years of age and older, presenting with at least one
vascular risk factor (e.g. smoking, hypertension, diabetes
mellitus, and hypercholesterolemia), without symptoms
of PAD. Based on the prevalence of PAD related to risk
factors, this PREVALENT clinical prediction model was
developed. Taking a score limit of 7 or more risk factor
points, resulting in a likelihood of approximately 20% or
higher for an ABI below 0.9, the following populations
should be screened. First, all current smokers of 55 years
or older should be screened by ABI. With a prevalence
of current smoking of approximately 20% in the popula-
tion of 55 years and older, approximately 139 patients
need to be screened in a general practice. A second
population that should be screened for asymptomatic
PAD are the subjects of 65 years or older with a history
of smoking of 10 or more packyears and non-adequately
treated hypertension, defined as a systolic blood pressure
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg.
Finally, the population of 75 years or older with non-
Table 2 Prevalence of PAD according to the clinical
prediction model in asymptomatic subjects
Score Prevalence (n) ABI*< 0.9 (n -%)
0 – 3 1202 84 (7.0)
4 706 84 (11.9)
5 924 134 (14.5)
6 865 151 (17.5)
7 920 178 (19.3)
8 722 170(23.5)
9 448 116 (25.9)
10 470 114 (24.3)
11 331 83 (25.1)
12 241 75 (31.1)
≥ 13 271 110 (40.6)
*ABI: ankle-brachial index.
Table 3 Overview of included international guidelines
with their recommended target population
Guideline Target population to perform an ABI
of asymptomatic subjects
ACCF/AHA 2011 [11] • Age 65 years and older





• Age 50–69 years with a history of smoking
or diabetes
• Age≥ 70 years
TASC II 2006 [5] • Age 50–69 years with cardiovascular
risk factors
• Age≥ 70 years
• Subjects with a 10-year risk of a
cardiovascular event between 10-20% in
whom further risk stratification is warranted
European guideline
2007 [6]
• Age≥ 50 years
American Diabetes
Association 2003 [13]
• Age> 50 years with diabetes
• If normal, the test should be repeated every
5 years
Prevention
conference V 2000 [16]
• Age≥ 50 years
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according to the PREVALENT clinical prediction model.
Based on this model, only 48% of the asymptomatic
population of 55 years and older will have a score of 7
or more, and are needed to be screened. Eventually, in
846 people an ABI below 0.9 will be measured using this
clinical prediction model, compared to 1,299 in the over-
all screened population of 55 years and older.
Furthermore, the time-investment of the ABI meas-
urement was studied. Patients of 55 years and older
with symptoms of intermittent claudication according
to the general practitioner (without confirmation by
ABI) and/or presenting with at least one vascular risk
factor, were asked to participate in this observational
study. There were no exclusion criteria. Informed con-
sent was obtained from eligible patients. For the meas-
urement of ABI, first the systolic brachial blood
pressure was performed by auscultation at both arms,
after which the systolic pressures of the dorsalis pedis
and posterior tibial arteries were measured at malleolar
level by an 8 MHz Doppler sound in both legs. The
ABI was calculated for each leg by dividing the highest
systolic ankle pressure by the highest brachial systolic
pressure. The ABI was measured by the general practi-
tioner or practice assistant. PAD was defined as a sin-
gle ABI measurement of less than 0.9 in one or both
legs.
After completing the case record form, the time
required for an ABI measurement was reported for each
patient. Furthermore, the general practitioner was asked
if he had previous experience with performing the ABI
measurement before participating in this study and who
actually performed the ABI (e.g. general practitioner or
practice assistant).
Finally, to explore the impact of the number needed to
screen on the required time investment by generalpractitioners in the Netherlands, the number needed to
screen was translated to general practice and related to
the time requirement of an ABI measurement.
The study protocol was approved by the medical eth-
ical committee of the Atrium Medical Centre Parkstad,
Heerlen, the Netherlands.Results
Contemporary guidelines
Overall, 6 international contemporary guidelines were
included where an ABI measurement is advised to per-
form as initial risk assessment for cardiovascular mor-
bidity [5,6,11,13,15,16]. Table 3 is showing an overview
of these included guidelines with the recommended tar-
get population to perform an ABI measurement. The ra-
tionale for screening subjects with diabetes is that PAD
is prevalent in patients with diabetes mellitus and is
more commonly asymptomatic and more likely to lead
to limb loss if a clinician waits until the onset of symp-
toms to identify disease [13]. It is suggested that the ABI
has the potential to increase the sensitivity, specificity,
and positive predictive values of cardiovascular risk. Al-
though establishment of PAD diagnosis in individuals at-
risk has the potential to alter the intensity of treatment
goals [11], it should be noted that the impact of early PAD
detection on either limb or cardiovascular ischemic event
outcomes or on survival, has not yet been evaluated in pro-
spective trials [11].
Table 4 Estimated prevalences* of vascular risk factors
Vascular risk factor Age≥ 50 years
Smoking
Current smokers  22.2% ( 20% for age≥ 55 years)
History of smoking  51%
Hypertension  41%
Diabetes Mellitus  10.2%
Hypercholesterolemia  34%
*Prevalences are based on the census of the Dutch population.
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The overall population of 55 years of age and older in
the Netherlands consists of approximately 4.9 million
people (29.6%), with approximately 2.1 million male
subjects [17].
Smoking
It is reported that in 2010 of the people between 50 to
55 years, 55 to 65 years, 65 years to 75 years and 75 years
and over respectively 31%, 25%, 18%, and 10% were
current smokers [17]. Distribution to the general popu-
lation in respective, taking the age band into account,
this corresponds to an overall percentage of approxi-
mately 22.2% current smokers in the population of
50 years and older. Furthermore, it is described that over
40% of the women and over 65% of men aged above
50 years were former smokers [18].
In the population of 55 years and older, these percen-
tages will be slightly less, due to the decreasing preva-
lence in older subjects, corresponding to approximately
20% current smokers.
Hypertension
Due to the recent change in the cut off points for the
definition of hypertension, there are no exact data avail-
able about the prevalence of hypertension, defined as a
systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg [19]. The ERGO study
showed a prevalence of 27% in the subjects of 55 to
59 years of age [20]. A cross sectional survey consisting
of 530 subjects of 55 years and older, found a prevalence
of hypertension of 41.7%, defined as systolic blood pres-
sure ≥140 mmHg and/or diastolic ≥90 mmHg [21].
Based on this, we estimated that there are currently ap-
proximately 2.04 million people of 55 years and older
with hypertension in the Netherlands.
Diabetes mellitus
Overall, there are approximately 696,150 patients with
known diabetes mellitus in the Netherlands [17]. Ap-
proximately 89% is above 50 years of age, corresponding
with approximately 620,000 subjects with diabetes
(10.2%) [17]. The incidence of new diabetes is estimated
to be approximately 58,090 subjects per year, with 82%
older than 50 years of age [22].
Hypercholesterolemia
No exact data about the prevalence of hypercholesterol-
emia are available due to the recent change in the cut off
levels for the definition of hypercholesterolemia. Dutch
data, using a definition of hypercholesterolemia of
6.5 mmol/l or higher and/or the use of lipid loweringmedi-
cation, estimated the prevalence of hypercholesterolemia
to be 33.9% in the population of 50 to 60 years of age [23].A summary of prevalences of these common vascular
risk factors are given in Table 4. Based on these inde-
pendent prevalence’s of these risk factors, it can be cal-
culated that less than 10% of subjects above 55 years are
without any vascular risk factor (22.2% smokers, 27%
subjects with hypertension, 10.2% subjects with diabetes
mellitus, and 33.9% subjects with hypercholesterolemia).
This low percentage is largely explained by current
smoking behaviour and the presence of diabetes.
Time-investment using the ABI
The study included 13,038 patients, performed by 955
general practices. Of the 513 general practitioners who
included ≥ 20 patients, 101 (19.7%) recorded to have ex-
perience performing the ABI prior to participation in
this study. The mean time necessary for ABI measure-
ment in the overall population was 17 minutes (SD: 7.4).
In 2,534 subjects (19.4%) ABI was measured by an
experienced general practitioner or practice assistant.
The influence of experience on the duration of ABI
measurement is shown in Table 5.
Feasibility of the ABI as screening tool in general practice
Supposing that a general practice consists of approxi-
mately 2,350 patients, screening of the overall popula-
tion of 50 years and older, according to the guidelines,
corresponds with approximately 36.7% of the total popu-
lation [17]. This results in a total of approximately 862
subjects per general practice who should be screened by
ABI measurement.
Thus, a single screening of ABI in the overall popula-
tion of 50 years and older would take an investment of
approximately 6 weeks (244 hours) of full time work.
Hence, a strategy of an ABI measurement in all subjects
of 50 years and older to be performed every 5 years car-
ries the burden of over one week full time work per year
(Figure 1). Limitation of screening subjects of 50 years
and older with at least one vascular risk factor only
would not substantially reduce this workload due to the
high prevalence of these vascular risk factors.
Using the PREVALENT clinical prediction model, first
all current smokers of 55 years or older should be
Table 5 Influence of experience on measurement time of the ABI
Included patients Time ABI measurement 1 (min) Mean (SD)
Experienced Non-experienced
GP 2 PA 3 GP 2 PA 3
Patient 1 13.5 (5.9) (n = 47) 19.7 (9.5) (n = 78) 18.0 (8.1) (n = 73) 19.1 (8.1) (n = 206)
Patient 2 14.2 (5.9) (n = 47) 18.8 (8.7) (n = 76) 16.7 (6.9) (n = 71) 19.0 (7.3) (n = 201)
Patient 3 13.1 (5.4) (n = 43) 19.6 (10.4) (n = 78) 17.1 (7.5) (n = 71) 18.8 (7.3) (n = 205)
Patient 4 12.4 (4.7) (n = 45) 18.4 (7.8) (n = 77) 16.6 (7.5) (n = 70) 18.1 (7.1) (n = 205)
Patient 5 12.6 (5.8) (n = 47) 18.4 (6.9) (n = 76) 16.4 (9.6) (n = 71) 18.1 (6.9) (n = 202)
Patient 6 – 10 12.8 (5.7) (n = 228) 17.8 (7.4) (n = 367) 16.0 (7.8) (n = 354) 18.0 (7.5) (n = 993)
Patient 11 – 15 12.2 (5.2) (n = 211) 17.7 (7.3) (n = 355) 15.3 (7.5) (n = 341) 17.5 (7.2) (n = 947)
Patient≥ 16 12.5 (5.4) (n = 200) 18.0 (7.5) (n = 347) 15.5 (7.2) (n = 335) 17.4 (6.9) (n = 936)
1Time ABI measurement included time needed to perform systolic pressures of the brachial artery at both arms and of the dorsalis pedis and posterior tibial
arteries at both legs. 2GP: general practitioner; 3PA: practice assistent.
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of approximately 20% in the population of 55 years and
older, approximately 139 patients need to be screened
in a general practice. The second population at risk are
subjects of ≥65 years with inadequately treated hyper-
tension, and a history of smoking behaviour. Since there
are approximately 359 patients of ≥65 years, withFigure 1 Feasibility of ABI screening..approximately 29.6% inadequately treated hypertension,
and approximately 51% former smokers, this results in
approximately 54 subjects to screen for asymptomatic
PAD in this subgroup. Assuming that in a general prac-
tice there are approximately 181 patients of 75 years
and older, with approximately 29.6% inadequately trea-
ted hypertension, there are approximately 54 subjects to
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the ABI screening using the clinical prediction model.
Overall, using the PREVALENT clinical prediction
model, 247 patients per general practice should be
screened for PAD by ABI measurement, corresponding
to approximately 70 working hours for an initial screen-
ing measurement. Of the screened subjects, 60% to 80%
will have a normal ABI (0.9 or higher). Screening these
non-PAD subjects every five years, implies that in the
following years approximately 150 to 200 subjects a
repeated ABI measurement will have to be performed to
diagnose asymptomatic PAD, excluding new subjects of
55 years of age. Hence, a strategy of an ABI measure-
ment in these subjects to be performed every 5 years will
only take approximately 11 working hours of full time
work per year to diagnose asymptomatic PAD (Figure 1).
Discussion
Following the recommendations of the current inter-
national guidelines regarding the use of an ABI measure-
ment, will substantially increase the workload of general
practitioners. The time requirement of 17 minutes per
measurement is comparable with earlier results [24]. Al-
though in the Netherlands the cost of measurement of
the ABI in office practice is reimbursed by healthcare
payers by an amount of 54.72 Euro for each ABI meas-
urement, it is doubtful if the recommendations are feas-
ible and can be followed in general practice, taking the
high time pressure into account.
Based on the PREVALENT clinical prediction model,
52% of the subjects of 55 years and older will not be
screened. Of these, approximately 12% will have an ABI
below 0.9. However, of the screened population, the
diagnosis PAD will be established by ABI measurement
in 25%. Overall, approximately 65% of the asymptomatic
patients with PAD will be found as a result of screening
using clinical prediction model and ABI measurement.
Clinical consequences of detecting a low ABI in
asymptomatic subjects
Current U.S. national hypertension and lipid treatment
guidelines include all patients with lower extremity PAD,
regardless of symptom status, as a high-risk category
[11]. In these guidelines, all patients should achieve risk
reduction and specific treatment targets comparable to
individuals with established coronary artery disease
[25,26].
Strengths and limitations of the study
This study is showing that screening the entire popula-
tion of 50 years and older, as is advised in current inter-
national guidelines, will not be feasible in general
practice, since the work involved is substantial. A more
rationale approach might be the screening of subgroupsof the population of 55 years and older based on
PREVALENT clinical prediction model. The work load
of screening can efficiently be reduced, while the major-
ity of asymptomatic subjects with PAD will be detected.
The main limitation of the present study is that the
clinical prediction model that is used in the calculations
has not been validated yet. Furthermore, there are no
exact data available of prevalences of vascular risk fac-
tors, making it difficult to do the calculations. Finally, no
benefit-cost ratio analysis is performed, which might
contribute even more to our statement that screening
the entire population is not feasible in general practice.
Conclusion
Screening for PAD by using ABI in the initial risk assess-
ment is recommended as additional measurement in the
population of 50 years and older. Screening the popula-
tion of 50 years and older as prescribed by international
guidelines, will not be feasible in general practice, since
the work involved is substantial. A more rationale ap-
proach might be the screening of subgroups of the
population of 55 years and older based on a clinical pre-
diction model. Our calculations suggest that using the
PREVALENT clinical risk score, the work load of screen-
ing can be reduced by 60% while the majority of asymp-
tomatic patients with PAD (63%) will be detected.
Ideally, cost effectiveness of screening with ABI meas-
urement should be assessed in future studies.
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